Αρχική World News Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus... World News Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab plus Gebasaxturev and Pembrolizumab Monotherapy in Stage IIIB–D Melanoma Από Ogkologos - 21 Ιανουαρίου, 2025 979 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a substudy 02C of the KEYMAKER-U02 trial Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Study Examines Whether Blood Test Can Identify Early Cancers 2 Ιουνίου, 2020 Moving Beyond BMI: Low Muscle Mass May Affect Cancer Survival 30 Απριλίου, 2018 Feeling the pull: Using magnetic drug targeting to improve chemotherapy in... 16 Φεβρουαρίου, 2023 Allergan Recalls Textured Breast Implants Worldwide Due To Cancer Risk At... 24 Ιουλίου, 2019 Φόρτωση περισσοτέρων HOT NEWS Study Suggests Reviewing Lung Cancer Screening Criteria for African Americans Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC... FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia Drug Regimen Boosts Survival of People with Advanced Colorectal Cancer